EMEA-001371-PIP03-22

Opinion/decision on a Paediatric investigation plan (PIP): Keytruda, Pembrolizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0096/2023

Traineeship - Frequently asked questions (FAQs)

Opinion/decision on a Paediatric investigation plan (PIP): Lumykras, sotorasib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Oncology, PIP number: P/0089/2023

EMEA-003166-PIP01-21

EMEA-003215-PIP01-22

List of industry subject matter experts and list of planned calls for industry subject matter experts

Referral: Pseudoephedrine-containing medicinal products, pseudoephedrine Article 31 referrals European Commission final decision, 25/01/2024, 27/03/2024, 04/04/2024

Human medicines European public assessment report (EPAR): Niapelf, paliperidone, Date of authorisation: 31/03/2024, Status: Authorised

Paediatric Committee (PDCO): 20-23 February 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 February 2024 to 23 February 2024